Combination of TLR1/2 and TLR3 ligands enhances CD4+ T cell longevity and antibody responses by modulating type I IFN production

• DOI: 10.1038/srep32526
• Publication Date: 2016-09-01T10:53:02Z
• Authors: Bo Ryeong Lee; Soo Kyung Jeong; Byung Cheol Ahn; Byeong-Jae Lee; Sung Jae Shin; Jung Sun Yum; Sang-Jun Ha
• Keywords: TLR3

Abstract Despite the possibility of combining Toll-like receptor (TLR) ligands as adjuvants to improve vaccine efficacy, it remains unclear which combinations TLR are effective or what their underlying mechanisms may be. Here, we investigated mechanism action L-pampo, a proprietary adjuvant composed TLR1/2 and TLR3 ligands. L-pampo dramatically increased humoral immune responses against tested target antigens, was correlated with an increase in follicular helper T cells maintenance antigen-specific CD4 + cells. During initial priming phase, contrast induction type I interferon (IFN) pro-inflammatory cytokines stimulated by polyI:C, showed greatly diminished IFN, but not other cytokines, remarkably attenuated IRF3 signaling, appeared be critical L-pampo-mediated adjuvanticity. Collectively, our results demonstrate that contributes promotion antibodies cell via fine regulation signaling pathways, helpful design improved vaccines.